Apollomics Inc. (APLM) Fair Value 2026

APLM · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

2.1 /10

32 fundamental signals · 8 models active

Value Trap Risk

— (—/100)

Quick Summary — As of 2026-07-15, Apollomics Inc. (APLM) trades at $19.19, approximately 390% above CirclFi’s Bayesian DCF fair value of $3.92. QOC: 2.1/10. 8/13 models active.

Key Facts

Ticker
APLM
Price
$19.19
Quality Score
2.1/10
Value Trap Risk
—/100
Models Active
8/13
Last Updated
Strength: First Chicago suggests +60.7% upside with 2% confidence
Risk: Below-average Quality Score of 2.1/10 signals weak fundamentals

Is Apollomics Inc. (APLM) Undervalued or Overvalued in 2026?

According to CirclFi’s 8-model valuation engine, Apollomics Inc. (APLM) appears overvalued as of : the median of 8 independent fair value estimates is $10.73, 44.1% below the current price of $19.19. Estimates range from $0.68 to $30.84. APLM scores 2.1/10 on fundamental quality and —/100 on value-trap risk.

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Apollomics Inc. Stock in 2026? →

Valuation Matrix

8 Intrinsic Value Models vs. Current Price ($19.19)

Core Models (Unlocked)
Model Fair Value Upside
Bayesian DCF
Low Conviction
 $3.92 -79.6%
CUCE Ensemble
Low Conviction
 $12.44 -35.2%
First Chicago
Low Conviction
 $30.84 +60.7%
PWERM
Low Conviction
 $18.92 -1.4%

Unlock the Full Matrix

Access 4 additional models including ML-RIV, Dynamic NAV, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 8 Models →

Cancel anytime · No contracts · Instant access

What Is Apollomics Inc. (APLM) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Apollomics Inc.'s intrinsic value is estimated at a composite fair value of $13.40. Trading at $19.19, the stock is approaching fair value or slight overvaluation (implied return of -30.2%), as 5 of 8 models suggest limited further upside. Notably, First Chicago sees the most upside at +60.7% (fair value: $30.84), while ML-RIV is the most conservative at -96.5% ($0.68). The spread between these extremes — +157.2% — reveals how different analytical frameworks can reach starkly different conclusions.

What Do the Models Say About APLM?

8 of 13 models are currently active for APLM. Of these, 2 models suggest upside while 6 models suggest overvaluation. The Bayesian DCF estimates APLM's intrinsic value at $3.92, implying -79.6% downside from the current price. See which stocks rank higher →

How Does APLM Rank in Biotechnology?

Among 76 Biotechnology stocks, APLM ranks #73 by Quality of Company score. CirclFi's QOC score of 2.1/10 evaluates 32 fundamental signals. A score of 2.1 signals below-average fundamentals.

See all Most Undervalued Biotechnology Stocks →

Apollomics Inc.'s positioning within the Biotechnology segment means that market exclusivity window plays an outsized role in fundamental analysis. The sector's unique characteristics — including breakthrough therapy designations — shape both the opportunity set and risk profile.

Is APLM a Value Trap?

The Value Trap algorithm is not active for APLM. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

8 of 13 models are active for Apollomics Inc.. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, Apollomics Inc. earns a quality score of 2.1/10. This concerning rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency.

The gap between the most bullish and bearish model spans +157.2% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every APLM valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across APLM's 8 active models, average confidence is 2%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Apollomics Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

8 related Biotechnology stocks with 13-model coverage

ADMAADMA Biologics IncQOC 10.0AUPHAurinia Pharmaceuticals IncQOC 9.5ACADACADIA Pharmaceuticals Inc.QOC 9.4ALNYAlnylam Pharmaceuticals, Inc.QOC 8.3ACRSAclaris Therapeutics, Inc.QOC 7.4ABCLAbCellera Biologics Inc.QOC 7.1ARCTArcturus Therapeutics Holdings QOC 7.0ARVNArvinas, Inc.QOC 6.9

Read investment analysis: ADMA · AUPH · ACAD · ALNY · ACRS

See all Biotechnology stocks ranked →

Frequently Asked Questions About Apollomics Inc.

What is Apollomics Inc.'s intrinsic value in 2026?

Based on CirclFi's 13-model analysis, Apollomics Inc. (APLM) has multiple fair value estimates. The Bayesian DCF model runs 10,000 Monte Carlo simulations with jump-diffusion to estimate intrinsic value at $3.92. The Quality of Company score is 2.1/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is APLM overvalued or undervalued right now?

At $19.19, 2 of 8 active models suggest APLM may be undervalued, while 6 indicate potential overvaluation. The median of all 8 fair value estimates is $10.73, 44.1% below the current price of $19.19 — a consensus view that APLM is overvalued. The assessment depends on which methodology best fits Apollomics Inc.'s business model in Biotechnology.

What does a Quality of Company score of 2.1 mean for APLM?

Apollomics Inc.'s QOC of 2.1/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on APLM?

CirclFi analyzes APLM with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 8 of 13 are active for this stock. Read the full methodology →

Is APLM a value trap in 2026?

CirclFi's Value Trap algorithm does not have sufficient data for APLM at this time. Browse stocks by value-trap risk →

Cite this analysis — “According to CirclFi’s 8-model valuation engine, Apollomics Inc. (APLM) has a median fair value of $10.73 — 44.1% below the current price of $19.19 — as of 2026-07-15.” Source: circlfi.com/stock/APLM/ · Methodology

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 8 mathematical frameworks give you clarity on APLM.

Unlock All 8 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access